SOLUTIONS PRODUCTS INNOVATION INVESTORS ESG
0
Add to list
GB COVID-19 Ag POCT
Cat. No. 4ECO101E
More details>
(3 items)
SOLUTIONS PRODUCTS INNOVATION INVESTORS ESG About GBC Our Brands R&D Media Join us Contact us
English 繁體中文
Menu
About Us
Reporting
Corporate Governance
FAQ
Investor News
Select Year:
{{news_year}}
{{y}}
{{n.a_date}}
{{n.a_title}}
Find Out More
Click for all news
COME CONNECT WITH US
投資者關係聯絡人 / 發言人
Frank Lin
G.M.
Phone:+886-3-577-9221 ext. 204
FAX:+886-3-577-9227
E-mail:frank.lin@gbc.com.tw
投資服務代理機構
First Securities
Phone:02-2563-5711
FAX:02-2563-5722
E-mail:tunghua.ho@firstsec.com.tw
Reporting
Financial Statements
Select Year:
{{fr_year}}
{{y}}
{{f["f_name_"+lang]}}
Investor News
Select Year:
{{news_year}}
{{y}}
{{n.a_date}}
{{n.a_title}}
More
Back to previous page
{{p+1}}
{{nshow.a_date}}
{{nshow.a_title}}
Back to previous page

Corporate Governance
Organization
Director
T.C. Lin
General Biologicals Corp. Chairman & CEO
Danner Lab Inc Chairman & CEO
Pacgen Life Science Chairman & CEO
CurieMed Corporation Chairman & CEO
GB GENES CORP. Board director
Taiwan Genomic Industry Alliance Inc. Board Director
Ace Medical Technology Co., Ltd Board Director
Pi-Hua Chen
CHLITINA Holding Limited. Chairman

Representative of Juristic Person of General Biologicals Corp.
Frank Lin
General Biologicals Corp. General Manager
Director of General Biologicals Corp.
GB GENES CORP. Chairman
Director of GB GENES CORP.
Representative of Juristic Person of GB GENES CORP.
Representative of Juristic Person of Viarich Biotechnology Co., Ltd
Jia-Zhen Lin
Coming Soon
Jian-Zhi Yeh
Coming Soon
Independent Director
Cheng-Hua Li (Independent Director and Audit Committee Member)
Coming Soon
Jen-Leigh Wu (Independent Director and Audit Committee Member)
Academia Sinica Visiting Chair Professor
NCKU Adjunct Professor
Moderator of the Ministry of Science and Technolohy
NTOU National Taiwan Ocean University Chair Professor
Independent Director, PRIT Biotech Co. Ltd.
Independent Director, General Biologicals Corp.
Cheryl Lin (Independent Director and Audit Committee Member)
President, Glonova Co.
Consultant, T-TOP Clinical Research Co.
Director, Yolk Partners Co.
Independent Director, General Biologicals Corp.
Rui-Hsun Chen (Independent Director and Audit Committee Member)
Coming Soon
FAQ
What is GBC's main business?
GBC is a world-leading supplier of in vitro diagnostics and solutions, mainly engaged in the R&D, manufacturing, marketing and service of in vitro diagnostics. At present, the company's products cover three main areas: in vitro diagnostics, life science (Life Science) and services, drugs and biological consumer products, and has the most complete product line in the same industry in China. The company's products and solutions have been used in more than 40 countries and regions around the world.
How big is the company now?
In 2021, the company has 120 employees worldwide.
How can I access the company's financial statements?
The electronic version of the company's financial report can be accessed on the website of the Public Information Observatory (https://mops.twse.com.tw) by entering the company code "4117" to view relevant information.
About Us
Founded in 1984, General Biologicals Corporation (GBC) is a pioneer in Taiwan’s in-vitro diagnostics (IVD) industry, originating from the National Hepatitis Prevention Program initiated by the Executive Yuan. For over 40 years, GBC has been committed to delivering innovative, accurate, and accessible diagnostic solutions that improve healthcare outcomes worldwide.

As a GMP-certified and ISO 13485-compliant manufacturer, GBC specializes in the research, development, production, and global distribution of advanced IVD products and integrated diagnostic technologies. Our solutions are trusted in 40+ countries, empowering hospitals, clinical laboratories, blood banks, and healthcare professionals with reliable, high-performance tools for disease detection and monitoring.

Core Expertise:
• Infectious & Respiratory Diseases
• Blood-Borne Viruses
• Fertility & Sexual Health
• Oncology & Tumor Markers
• Human Genetics
• Emerging Infectious Diseases
By leveraging protein-based and nucleic acid-based diagnostic platforms, GBC has built a fully integrated value chain — spanning R&D, manufacturing, clinical applications, and laboratory services — enabling breakthroughs in precision diagnostics.

Looking forward, GBC is extending beyond traditional IVD into next-generation healthcare solutions through its subsidiaries:
• CurieMed & Danner Lab — Digital medical diagnostics and clinical laboratory services
• GBP — P113 antimicrobial peptide (AMP) therapeutics and consumer healthcare innovations

With a strong global presence, cutting-edge technologies, and a mission to make world-class diagnostics and therapeutics accessible to all, GBC is transforming healthcare and empowering better lives.
About GBC
{{f["f_name_"+lang]}}